TJ Talks

Outcomes that Matter: a Common Sense Revolution in Oncology

Caught between enthusiasm for technical innovation and the need for a critical assessment of research practices, the oncology is seeking a new path that offers real hope for effective treatments and a fair distribution of resources for the benefit of patients, because, as Prof. Gyawali’s elderly patient suggests, the real issue is that the quality of life depends entirely on the patient's perspective, which should not be ignored. Enjoy listening to this episode of TJ Talks: a passionate reflection on the therapeutic approach, the balance between the acceleration of innovation and what has been proven to work, and the urgent need for a common-sense revolution in oncology. Prof. Bishal Gyawali is medical oncology and professor at Queen's University, (Canada) and, together with Dr Dario Trapani (medical oncologist at the IEO, Milan, Italy) - who is hosting the podcast on this occasion - is one of the founders of the Common Sense Oncology Movement, launched in 2023. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Integrare razionalità clinica e responsabilità sistemica: il Common Sense Oncology in Italia

Imparare a governare l'innovazione: questo l'invito che il cosiddetto Common Sense Oncology rivolge alla comunità oncologica per un approccio terapeutico interamente centrato sui bisogni del paziente. Alla base del ragionamento c'è una domanda semplice: siamo sicuri che più trattamento significhi sempre migliore medicina? E per comprendere cosa comporti trasformare questo principio in politica clinica nel contesto italiano, il dr. Dario Trapani ha incontrato per TJ Talks il prof. Massimo Di Maio, Presidente AIOM, e il dr. Francesco Perrone, Presidente della Fondazione AIOM, impegnati da tempo a portare il Common Sense Oncology dal piano del dibattito a quello dell'azione. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Tackling the clinical challenges of GU Oncology

From advances in the screening of prostate cancer to the management of the genitourinary tumors, the GU oncology addresses ever more clinical challenges.  What are the most relevant challenges in the management of the prostate cancer population? "It is crucial to balance the right treatment strategy with the right endpoint for patients": Professor Silke Gillessen gets straight to the point of the question posed by Dr Giuseppe Procopio, Head of the Department of Genitourinary Medical Oncology Unit at IRCCS National Cancer Institute Milan, and Editor of the GU Section of the Tumori Journal. The guest expert of this TJ Talks podcast is Silke Gillessen, Medical and Scientific Director of the Oncology Institute of Southern Switzerland and Full Professor at University of Italian Switzerland, focusing her research in genitourinary areas. In terms of endpoints - she continues - overall survival is the gold endpoint. But when it comes to metastatic prostate cancer, it is necessary to aim for a mix of quality of life, which is very important, and oncological outcomes. These should include improvements related to patients' quality of life, such as time to progression and time to symptomatic events. Patients remind us that we must think not only about the disease, but also about their well-being. Learn more about the genitourinary cancer care scenario from one of the leading voices in the field. Enjoy your listening! See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Primary and Surrogate Endpoints in Clinical Trials: Implementation and Challenges in Daily Practice

The choice of an endpoint can really change the way a treatment is administered or approved for use on patients. And in the future, we will see much more data on quality of life, and trials will probably also work on validating surrogate endpoints and biomarkers.  In this TJ Talks dedicated to the hot topic of endpoints in clinical trials, Gabriele Zoppoli, Associate Professor of Medicine at University of Genoa and Internal Medicine Consultant at Policlinico San Martino (Genoa) meet Erman Akkus, MD at Ankara University, Faculty of Medicine, Department of Medical Oncology. Alongside “primary clinical endpoints”, which concern overall survival and quality of life, surrogate endpoints are early or indirect measures of these primary endpoints, such as progression-free survival and response rate. Their purpose? To facilitate clinical trials and drug approval, but surrogate endpoints are still an active area of research and are the subject of debate in oncology. Meanwhile, patients' perceptions are waiting to be taken more seriously. Get insights, listen to the TJ Talks podcast See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Pharmaco-prevention in Breast Cancer: a strategy to halve the incidence of a potentially fatal disease

Pharmaco-prevention of breast cancer is an evidence-based strategy that uses drugs to reduce the risk of disease in high-risk women. However, the use of this strategy remains modest due to concerns about toxicity, low awareness and difficulties in patient selection. In this TJ Talks podcast, together with Prof. Andrea De Censi, director of the Breast Unit at the Champalimaud Foundation in Lisbon, Portugal, here in conversation with Prof. Antonino Musolino (director of the Medical Oncology Unit at the IRCCS-Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Forlì-Cesena), we will examine what practical solutions can bridge the gap between pharmacological prevention, indication and adoption, with a look at the future perspectives in this setting. Enjoy your listening! See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.